Skip to content

17A in patients with widespread moderate-to-severe psoriasis

We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. Two recent Phase III randomized clinical studies investigated the safety and efficacy of targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. Psoriasis patients experience widespread bone loss. Treating psoriasis patients with IL-17 blockers — some already on the market — could have a beneficial effect on the loss of bone tissue, unlike other compounds that might only affect skin inflammation, says Ulu kan. Patients with moderate-to-severe plaque psoriasis achieve significant improvement with ixekizumab.

TREATMENT OF GENERALISED PUSTULAR PSORIASIS WITH ISOTRETINOIN 2Moderate-to-severe psoriasis is typically defined as involvement of more than 5 to 10 percent of the body surface area (the entire palmar surface, including fingers, of one hand is approximately 1 percent of the body surface area 7 ) or involvement of the face, palm or sole, or disease that is otherwise disabling. The patient has widespread severe disease. Ixekizumab. In two prospective, double-blind, multicentre, phase 3 studies (UNCOVER-2 and UNCOVER-3), patients with widespread moderate to severe psoriasis were randomly assigned (1:2:2:2) to receive placebo, etanercept (50 mg twice weekly), or one injection of 80 mg ixekizumab every 2 weeks, or every 4 weeks after a 160 mg starting dose. An assessment of any patient with psoriasis should include disease severity, the impact of disease on physical, psychological and social well-being, whether they have psoriatic arthritis, and the presence of any comorbidities. Topical use of potent corticosteroids on widespread psoriasis can lead to systemic as well as to local side-effects and the development of complications such as erythroderma or generalised pustular psoriasis. Epub 2009 Dec 17.

Psoriasis treatments can be divided into three main types: topical treatments, light therapy and systemic medications. These powerful anti-inflammatory drugs are the most frequently prescribed medications for treating mild to moderate psoriasis. Low-potency corticosteroid ointments are usually recommended for sensitive areas, such as your face or skin folds, and for treating widespread patches of damaged skin. This more aggressive treatment consistently improves skin and is often used for more-severe cases of psoriasis. June 17, 2015 References. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction. Treatments for moderate-to-severe psoriasis often do not meet patient and physician expectations due to adverse effects, lack of long-term efficacy, and inconvenient administration schedules.

Treatment Of Psoriasis

TREATMENT OF GENERALISED PUSTULAR PSORIASIS WITH ISOTRETINOIN 3It is the first IL-17 inhibitor to be approved for any indication in the US. UVB phototherapy can be used when the disease is more widespread or unresponsive to topical therapy. For patients with moderate to severe disease, systemic options include methotrexate, cyclosporine, the oral retinoid acitretin, and biologic therapy. After providing informed written consent, 4 adult patients with widespread vitiligo (covering a body surface area greater than or equal to 5 ) were treated with weekly intra-muscular injections of 15 mg alefacept for 12 weeks. A total of 766 patients with moderate-to-severe psoriasis were randomly assigned to receive ustekinumab 45 mg (n 255) or 90 mg (n 256) at weeks 0 and 4 and then every 12 weeks; or placebo (n 255) at weeks 0 and 4, with subsequent cross-over to ustekinumab at week 12. Psoriasis is a long-lasting autoimmune disease characterized by patches of abnormal skin. Erythrodermic psoriasis occurs when the rash becomes very widespread, and can develop from any of the other types. About 75 of cases can be managed with creams alone. Cosentyx (at a dose of 300 mg) is the first and only interleukin-17A (IL-17A) inhibitor approved to treat adult patients with moderate-to-severe plaque psoriasis. Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction. Scapho (secukinumab) has been approved by the Drug Controller General of India (DCGI) for the treatment of moderate-to-severe plaque psoriasis in adult patients. Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction. J Investig Dermatol Symp. Novartis secukinumab is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients. Nearly 35 of psoriasis patients suffer from moderate-to-severe plaque psoriasis10. Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction.

Psoriasis Treatments And Drugs

CHMP opinion for first-line treatment of moderate-to-severe psoriasis patients RNS – regulatory news service – news. Secukinumab (at a dose of 300 mg) is the first interleukin-17A (IL-17A) inhibitor to be recommended as a first-line treatment option for psoriasis patients who require systemic therapy in Europe. Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction. Efalizumab was approved for use in moderate to severe plaque psoriasis in adults 31-33. Data show patients rapidly achieved almost clear skin (PASI 90), consistent with head-to-head phase III FIXTURE psoriasis study where secukinumab showed superiority over Enbrel (etanercept) 5. Secukinumab is the first IL-17A inhibitor with phase III data presented and regulatory submissions filed with global health authorities. Phase III results for secukinumab in moderate-to-severe plaque psoriasis were first presented in October 2013, with additional results to be presented in 2014 for both moderate-to-severe plaque psoriasis and arthritic conditions (psoriatic arthritis and ankylosing spondylitis). Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis.

Cosentyx: First IL-17A Antagonist for Moderate-to-Severe Plaque Psoriasis Now Approved in Canada. Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment Dissatisfaction.